BACKGROUND: Low-density lipoprotein (LDL) can be oxidatively modified by reactive oxygen species, thus generating oxLDL. The latter induce formation of specific antibodies (oxLDLAb), which are detectable in patients with atherosclerosis, in which they might play a pathogenic or a protective role. Thus, we aimed to investigate the association of antibodies with oxidized LDLs (oxLDL) (oxLDLAbs) with coronary artery disease (CAD) and acute coronary syndromes. METHODS AND RESULTS: In a cross-sectional study of 529 consecutive patients undergoing quantitative coronary angiography for suspected CAD, we measured the titer of IgG oxLDLAbs by ELISA. With regression analysis techniques, we also investigated the determinants of oxLDLAb titer and the association of oxLDLAbs with CAD severity. We found no significant differences of oxLDLAb titer between groups of patients without and with different CAD severity. The oxLDLAb titer was 18.6 enzyme units (EU) (11.5 to 25.7 EU/mL) (mean, 95% CI) in patients without CAD; 16.8 EU (9.6 to 24.2 EU) in patients with stenosis <50%; and 19.9 EU (15 to 24.8 EU), 17.2 (13.8 to 20.6 EU), and 14.7 EU (12.1 to 17.3 EU) in those with in 1-, 2-, or 3-vessel > or =50% stenosis, respectively. Similarly, no differences of oxLDLAb titer between patients without and with acute coronary syndrome were found. The oxLDLAb titer correlated weakly with aging and with serum total, LDL, and HDL cholesterol and plasma homocysteine levels; however, only age and HDL cholesterol remained significant predictors of the oxLDLAb titer at a stepwise regression analysis. CONCLUSIONS: The results of this study, which was adequately powered from the statistical standpoint, provided no evidence for an association of IgG oxLDLAb titer with angiographically assessed CAD in whites.
BACKGROUND: Low-density lipoprotein (LDL) can be oxidatively modified by reactive oxygen species, thus generating oxLDL. The latter induce formation of specific antibodies (oxLDLAb), which are detectable in patients with atherosclerosis, in which they might play a pathogenic or a protective role. Thus, we aimed to investigate the association of antibodies with oxidized LDLs (oxLDL) (oxLDLAbs) with coronary artery disease (CAD) and acute coronary syndromes. METHODS AND RESULTS: In a cross-sectional study of 529 consecutive patients undergoing quantitative coronary angiography for suspected CAD, we measured the titer of IgG oxLDLAbs by ELISA. With regression analysis techniques, we also investigated the determinants of oxLDLAb titer and the association of oxLDLAbs with CAD severity. We found no significant differences of oxLDLAb titer between groups of patients without and with different CAD severity. The oxLDLAb titer was 18.6 enzyme units (EU) (11.5 to 25.7 EU/mL) (mean, 95% CI) in patients without CAD; 16.8 EU (9.6 to 24.2 EU) in patients with stenosis <50%; and 19.9 EU (15 to 24.8 EU), 17.2 (13.8 to 20.6 EU), and 14.7 EU (12.1 to 17.3 EU) in those with in 1-, 2-, or 3-vessel > or =50% stenosis, respectively. Similarly, no differences of oxLDLAb titer between patients without and with acute coronary syndrome were found. The oxLDLAb titer correlated weakly with aging and with serum total, LDL, and HDL cholesterol and plasma homocysteine levels; however, only age and HDL cholesterol remained significant predictors of the oxLDLAb titer at a stepwise regression analysis. CONCLUSIONS: The results of this study, which was adequately powered from the statistical standpoint, provided no evidence for an association of IgG oxLDLAb titer with angiographically assessed CAD in whites.
Authors: Anand Prasad; Paul Clopton; Colby Ayers; Amit Khera; James A de Lemos; Joseph L Witztum; Sotirios Tsimikas Journal: Arterioscler Thromb Vasc Biol Date: 2017-05-04 Impact factor: 8.311
Authors: Qi Chen; Steven E Reis; Candace Kammerer; Wendy Craig; Dennis M McNamara; Richard Holubkov; Barry L Sharaf; George Sopko; Daniel F Pauly; C Noel Bairey Merz; M Ilyas Kamboh Journal: J Lipid Res Date: 2011-01-20 Impact factor: 5.922
Authors: Fangwen Rao; Andrew J Schork; Adam X Maihofer; Caroline M Nievergelt; Santica M Marcovina; Elizabeth R Miller; Joseph L Witztum; Daniel T O'Connor; Sotirios Tsimikas Journal: Arterioscler Thromb Vasc Biol Date: 2015-05-07 Impact factor: 8.311
Authors: Thiruvelselvan Ponnusamy; Srikanth K Venkatachala; Manjunatha Ramanjappa; Vijay V Kakkar; Lakshmi A Mundkur Journal: Heart Asia Date: 2018-06-26
Authors: Giuseppe Maiolino; Luigi Pedon; Maurizio Cesari; Anna Chiara Frigo; Robert L Wolfert; Marlena Barisa; Leopoldo Pagliani; Giacomo Rossitto; Teresa Maria Seccia; Mario Zanchetta; Gian Paolo Rossi Journal: PLoS One Date: 2012-10-31 Impact factor: 3.240
Authors: G N Fredrikson; D V Anand; D Hopkins; R Corder; R Alm; E Bengtsson; P K Shah; A Lahiri; J Nilsson Journal: Diabetologia Date: 2009-05-12 Impact factor: 10.122
Authors: Lourdes Garrido-Sánchez; Jose M García-Almeida; Sara García-Serrano; Isabel Cardona; Juan García-Arnes; Federico Soriguer; Francisco J Tinahones; Eduardo García-Fuentes Journal: Diabetes Care Date: 2008-10-03 Impact factor: 17.152
Authors: Giuseppe Maiolino; Giacomo Rossitto; Paola Caielli; Valeria Bisogni; Gian Paolo Rossi; Lorenzo A Calò Journal: Mediators Inflamm Date: 2013-10-03 Impact factor: 4.711